During this meeting, the advisory committee will: Review available safety and efficacy data for BPC-157, including preclinical studies and any available clinical evidence Consider public comments submitted by patients, practitioners, and industry stakeholders Evaluate the clinical need for compounded BPC-157 and the patient populations that would benefit Assess the compounding quality considerations specific to peptide formulations Issue a recommendation to the FDA on whether BPC-157 should be included on the 503A compounding list Possible outcomes include: Positive recommendation: PCAC advises the FDA to add BPC-157 to the 503A list, clearing the way for legal compounding nationwide
Decisions by the committee are consequential
A recent in vitro study showed that PINK1-dependent phosphorylation of Ser111 of Rab8A antagonistically regulates the phosphorylation of Thr72 of Rab8A by LRRK2 (Vieweg et al., 2020), suggesting that there might be even closer crosstalk between the two master kinase
How to Use: Mix one packet with water, stir, and drink
Labs are rechecked every 90 days so your dose is adjusted to how you're actually responding not to how you're expected to respond
All ANS Drugs ANS Neurotransmitters & Hormones Acetylcholine Trade Name: Miochol-E Drug Class: Cholinomimetic (direct acting muscarinic & nicotinic agonist) Mechanism of Action: The endogenous agonist for muscarinic and nicotinic receptors
